Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced the completion of the submission of its New Drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback